SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 2nd, 2021 • Essetifin SPA • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 28, 2021, between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
JOINT FILING AGREEMENTJoint Filing Agreement • July 2nd, 2021 • Essetifin SPA • Pharmaceutical preparations
The undersigned hereby agree that the Schedule 13D with respect to the Common Stock of RegeneRx Biopharmaceuticals, Inc. dated as of July 2, 2021, is, and any amendments thereto signed by such of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934.
